Poly(ethylene glycol) Hydrogels with the Sustained Release of Hepatocyte Growth Factor for Enhancing Vascular Regeneration
The surface modification of biologically active factors on tissue-engineering vascular scaffold fails to fulfill the mechanical property and bioactive compounds' sustained release in vivo and results in the inhibition of tissue regeneration of small-diameter vascular grafts in vascular replacement therapies. In this study, biodegradable poly(ε-caprolactone) (PCL) was applied for scaffold preparation, and poly(ethylene glycol) (PG) hydrogel was used to load heparin and hepatocyte growth factor (HGF). In vitro analysis demonstrated that the PCL scaffold could inhibit the heparin release from the PG hydrogel, and the PG hydrogel could inhibit heparin release during the process of PCL degradation. Finally, it results in sustained release of HGF and heparin from the PCL-PG-HGF scaffold. The mechanical property of this hybrid scaffold improved after being coated with the PG hydrogel. In addition, the PCL-PG-HGF scaffold illustrated no inflammatory lesions, organ damage, or biological toxicity in all primary organs, with rapid organization of the endothelial cell layer, smooth muscle regeneration, and extracellular matrix formation. These results indicated that the PCL-PG-HGF scaffold is biocompatible and provides a microenvironment in which a tissue-engineered vascular graft with anticoagulant properties allows regeneration of vascular tissue (Scheme 1). Such findings confirm the feasibility of creating hydrogel scaffolds coated with bioactive factors to prepare novel vascular grafts.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
ACS applied bio materials - 6(2023), 12 vom: 18. Dez., Seite 5252-5263 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xu, Zeqin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.12.2023 Date Revised 19.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acsabm.3c00516 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364476265 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364476265 | ||
| 003 | DE-627 | ||
| 005 | 20231227134432.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acsabm.3c00516 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1232.xml |
| 035 | |a (DE-627)NLM364476265 | ||
| 035 | |a (NLM)37955977 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xu, Zeqin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Poly(ethylene glycol) Hydrogels with the Sustained Release of Hepatocyte Growth Factor for Enhancing Vascular Regeneration |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.12.2023 | ||
| 500 | |a Date Revised 19.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The surface modification of biologically active factors on tissue-engineering vascular scaffold fails to fulfill the mechanical property and bioactive compounds' sustained release in vivo and results in the inhibition of tissue regeneration of small-diameter vascular grafts in vascular replacement therapies. In this study, biodegradable poly(ε-caprolactone) (PCL) was applied for scaffold preparation, and poly(ethylene glycol) (PG) hydrogel was used to load heparin and hepatocyte growth factor (HGF). In vitro analysis demonstrated that the PCL scaffold could inhibit the heparin release from the PG hydrogel, and the PG hydrogel could inhibit heparin release during the process of PCL degradation. Finally, it results in sustained release of HGF and heparin from the PCL-PG-HGF scaffold. The mechanical property of this hybrid scaffold improved after being coated with the PG hydrogel. In addition, the PCL-PG-HGF scaffold illustrated no inflammatory lesions, organ damage, or biological toxicity in all primary organs, with rapid organization of the endothelial cell layer, smooth muscle regeneration, and extracellular matrix formation. These results indicated that the PCL-PG-HGF scaffold is biocompatible and provides a microenvironment in which a tissue-engineered vascular graft with anticoagulant properties allows regeneration of vascular tissue (Scheme 1). Such findings confirm the feasibility of creating hydrogel scaffolds coated with bioactive factors to prepare novel vascular grafts | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a hepatocyte growth factor | |
| 650 | 4 | |a poly(ethylene glycol) | |
| 650 | 4 | |a poly(ε-caprolactone) | |
| 650 | 4 | |a surface modification | |
| 650 | 4 | |a vascular regeneration | |
| 650 | 7 | |a Hepatocyte Growth Factor |2 NLM | |
| 650 | 7 | |a 67256-21-7 |2 NLM | |
| 650 | 7 | |a Delayed-Action Preparations |2 NLM | |
| 650 | 7 | |a Biocompatible Materials |2 NLM | |
| 650 | 7 | |a Polyethylene Glycols |2 NLM | |
| 650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
| 650 | 7 | |a Hydrogels |2 NLM | |
| 650 | 7 | |a Heparin |2 NLM | |
| 650 | 7 | |a 9005-49-6 |2 NLM | |
| 700 | 1 | |a Geng, Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Tong, Zhu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Liqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Xing, Yuehao |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Zengguo |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Yongquan |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Lianrui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACS applied bio materials |d 2018 |g 6(2023), 12 vom: 18. Dez., Seite 5252-5263 |w (DE-627)NLM287335372 |x 2576-6422 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2023 |g number:12 |g day:18 |g month:12 |g pages:5252-5263 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acsabm.3c00516 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2023 |e 12 |b 18 |c 12 |h 5252-5263 | ||